Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

Kramer RM, Archer MC, Orr MT, Dubois Cauwelaert N, Beebe EA, Huang PD, Dowling QM, Schwartz AM, Fedor DM, Vedvick TS, Fox CB.

Int J Nanomedicine. 2018 Jun 26;13:3689-3711. doi: 10.2147/IJN.S159839. eCollection 2018.

2.

Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical Cartridge.

Barnes V L, Fedor DM, Williams S, Dowling QM, Archer MC, Cloutier S, Parker S, Vedvick TS, Fox CB, Kramer RM.

AAPS PharmSciTech. 2017 Aug;18(6):2077-2084. doi: 10.1208/s12249-016-0688-7. Epub 2016 Dec 20.

PMID:
28000085
3.

The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.

Espinosa DA, Vega-Rodriguez J, Flores-Garcia Y, Noe AR, Muñoz C, Coleman R, Bruck T, Haney K, Stevens A, Retallack D, Allen J, Vedvick TS, Fox CB, Reed SG, Howard RF, Salman AM, Janse CJ, Khan SM, Zavala F, Gutierrez GM.

Infect Immun. 2017 Jan 26;85(2). pii: e00498-16. doi: 10.1128/IAI.00498-16. Print 2017 Feb.

4.

Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.

Stavaru C, Onu A, Lupulescu E, Tucureanu C, Rasid O, Vlase E, Coman C, Caras I, Ghiorghisor A, Berbecila L, Tofan V, Bowen RA, Marlenee N, Hartwig A, Bielefeldt-Ohmann H, Baldwin SL, Van Hoeven N, Vedvick TS, Huynh C, O'Hara MK, Noah DL, Fox CB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30.

5.

A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.

Noe AR, Espinosa D, Li X, Coelho-Dos-Reis JG, Funakoshi R, Giardina S, Jin H, Retallack DM, Haverstock R, Allen JR, Vedvick TS, Fox CB, Reed SG, Ayala R, Roberts B, Winram SB, Sacci J, Tsuji M, Zavala F, Gutierrez GM.

PLoS One. 2014 Sep 23;9(9):e107764. doi: 10.1371/journal.pone.0107764. eCollection 2014.

6.

Quantitative measurement of Toll-like receptor 4 agonists adsorbed to Alhydrogel(®) by Fourier transform infrared-attenuated total reflectance spectroscopy.

Dowling QM, Schwartz AM, Vedvick TS, Fox CB, Kramer RM.

J Pharm Sci. 2015 Feb;104(2):768-74. doi: 10.1002/jps.24180. Epub 2014 Sep 19.

PMID:
25242027
7.

Working together: interactions between vaccine antigens and adjuvants.

Fox CB, Kramer RM, Barnes V L, Dowling QM, Vedvick TS.

Ther Adv Vaccines. 2013 May;1(1):7-20. doi: 10.1177/2051013613480144.

8.

Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes.

Fox CB, Mulligan SK, Sung J, Dowling QM, Fung HW, Vedvick TS, Coler RN.

Int J Nanomedicine. 2014 Mar 11;9:1367-77. doi: 10.2147/IJN.S56582. eCollection 2014.

9.

Modulating potency: Physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity.

Dowling QM, Sivananthan SJ, Guderian JA, Moutaftsi M, Chesko JD, Fox CB, Vedvick TS, Kramer RM.

J Pharm Sci. 2014 Mar;103(3):879-89. doi: 10.1002/jps.23868. Epub 2014 Jan 24.

PMID:
24464844
10.

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Orr MT, Kramer RM, Barnes L 5th, Dowling QM, Desbien AL, Beebe EA, Laurance JD, Fox CB, Reed SG, Coler RN, Vedvick TS.

J Control Release. 2014 Mar 10;177:20-6. doi: 10.1016/j.jconrel.2013.12.025. Epub 2013 Dec 29.

11.

Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity.

Fung HW, Mikasa TJ, Vergara J, Sivananthan SJ, Guderian JA, Duthie MS, Vedvick TS, Fox CB.

J Nanobiotechnology. 2013 Dec 21;11:43. doi: 10.1186/1477-3155-11-43.

12.

In vitro evaluation of TLR4 agonist activity: formulation effects.

Misquith A, Fung HW, Dowling QM, Guderian JA, Vedvick TS, Fox CB.

Colloids Surf B Biointerfaces. 2014 Jan 1;113:312-9. doi: 10.1016/j.colsurfb.2013.09.006. Epub 2013 Sep 19.

13.

TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.

Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, Coler RN, Reed SG.

Vaccine. 2013 Dec 2;31(49):5848-55. doi: 10.1016/j.vaccine.2013.09.069. Epub 2013 Oct 10.

PMID:
24120675
14.

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, Lin S, Phan T, Moon JJ, Vedvick TS, Reed SG, Coler RN.

J Control Release. 2013 Nov 28;172(1):190-200. doi: 10.1016/j.jconrel.2013.07.030. Epub 2013 Aug 9.

15.

Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G.

Vaccine. 2013 Feb 18;31(9):1298-304. doi: 10.1016/j.vaccine.2012.12.076. Epub 2013 Jan 9.

16.

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.

Fox CB, Barnes V L, Evers T, Chesko JD, Vedvick TS, Coler RN, Reed SG, Baldwin SL.

Influenza Other Respir Viruses. 2013 Sep;7(5):815-26. doi: 10.1111/irv.12031. Epub 2012 Nov 5.

17.

Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Fox CB, Baldwin SL, Vedvick TS, Angov E, Reed SG.

Clin Vaccine Immunol. 2012 Oct;19(10):1633-40. Epub 2012 Aug 15.

18.

Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.

Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS.

AAPS PharmSciTech. 2012 Jun;13(2):498-506. doi: 10.1208/s12249-012-9771-x. Epub 2012 Mar 14.

19.

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS.

Vaccine. 2011 Nov 28;29(51):9563-72. doi: 10.1016/j.vaccine.2011.08.089. Epub 2011 Sep 9.

20.

Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse CF, Howard RF, Yadava A.

Infect Immun. 2011 Sep;79(9):3492-500. doi: 10.1128/IAI.05257-11. Epub 2011 Jun 20.

21.

KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Goto Y, Bhatia A, Raman VS, Liang H, Mohamath R, Picone AF, Vidal SE, Vedvick TS, Howard RF, Reed SG.

Clin Vaccine Immunol. 2011 Jul;18(7):1118-24. doi: 10.1128/CVI.05024-11. Epub 2011 Jun 1.

22.

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate.

Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M.

Vaccine. 2011 Apr 12;29(17):3284-92. doi: 10.1016/j.vaccine.2011.02.022. Epub 2011 Feb 22.

PMID:
21349366
23.

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG.

PLoS One. 2011 Jan 26;6(1):e16333. doi: 10.1371/journal.pone.0016333.

24.

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, Lu X, DeVos J, Hancock K, Katz JM, Vedvick TS, Duthie MS, Clegg CH, Van Hoeven N, Reed SG.

PLoS One. 2010 Oct 27;5(10):e13677. doi: 10.1371/journal.pone.0013677.

25.

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG.

Sci Transl Med. 2010 Oct 13;2(53):53ra74. doi: 10.1126/scitranslmed.3001094.

26.

Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions.

Fox CB, Lin S, Sivananthan SJ, Dutill TS, Forseth KT, Reed SG, Vedvick TS.

Pharm Dev Technol. 2011 Oct;16(5):511-9. doi: 10.3109/10837450.2010.495397. Epub 2010 Jun 16.

PMID:
20550484
27.

Optimized subunit vaccine protects against experimental leishmaniasis.

Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, Coler RN, Vedvick TS, Reed SG.

Vaccine. 2009 Nov 23;27(50):7036-45. doi: 10.1016/j.vaccine.2009.09.066. Epub 2009 Sep 26.

28.

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.

Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta GR, Chesko J, Coler RN, Friede M, Reed SG, Vedvick TS.

Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):123-32. doi: 10.1016/j.colsurfb.2009.08.022. Epub 2009 Aug 20.

PMID:
19748238
29.

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, Mompoint F, Vedvick TS, Bertholet S, Coler RN, Reed SG.

Vaccine. 2009 Oct 9;27(43):5956-63. doi: 10.1016/j.vaccine.2009.07.081. Epub 2009 Aug 11.

PMID:
19679214
30.

Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.

Guo X, Barroso L, Becker SM, Lyerly DM, Vedvick TS, Reed SG, Petri WA Jr, Houpt ER.

Infect Immun. 2009 Sep;77(9):3909-18. doi: 10.1128/IAI.00487-09. Epub 2009 Jun 29.

31.

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.

Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, Vedvick TS, Reed SG, Coler RN.

Vaccine. 2009 May 18;27(23):3063-71. doi: 10.1016/j.vaccine.2009.03.018. Epub 2009 Mar 26.

32.

Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, Reed SG.

J Immunol. 2008 Dec 1;181(11):7948-57.

33.

Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions.

Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS.

Colloids Surf B Biointerfaces. 2008 Aug 1;65(1):98-105. doi: 10.1016/j.colsurfb.2008.03.003. Epub 2008 Mar 22.

PMID:
18440205
34.

Physical stabilization of Norwalk virus-like particles.

Kissmann J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedvick TS, Middaugh CR.

J Pharm Sci. 2008 Oct;97(10):4208-18. doi: 10.1002/jps.21315.

PMID:
18300304
35.

Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature.

Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR.

J Biol Chem. 2006 Jul 14;281(28):19478-88. Epub 2006 May 4.

37.

Serum antibodies to lipophilin B detected in late stage breast cancer patients.

Carter D, Dillon DC, Reynolds LD, Retter MW, Fanger G, Molesh DA, Sleath PR, McNeill PD, Vedvick TS, Reed SG, Persing DH, Houghton RL.

Clin Cancer Res. 2003 Feb;9(2):749-54.

38.

Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer.

Carter D, Douglass JF, Cornellison CD, Retter MW, Johnson JC, Bennington AA, Fleming TP, Reed SG, Houghton RL, Diamond DL, Vedvick TS.

Biochemistry. 2002 May 28;41(21):6714-22.

PMID:
12022875
39.

Chemical deglycosylation can induce methylation, succinimide formation, and isomerization.

Douglass JF, Jaya NN, Vedvick TS, Reed SG, Zhang Y, Carter D.

J Protein Chem. 2001 Oct;20(7):571-6.

PMID:
11838545
40.

A p53 homologue and a novel serine proteinase inhibitor are over-expressed in lung squamous cell carcinoma.

Wang T, Hopkins DA, Fan L, Fanger GR, Houghton R, Vedvick TS, Repasky E, Reed SG.

Lung Cancer. 2001 Dec;34(3):363-74.

PMID:
11714533
41.

Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy.

Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, Zou-Yang XH, Onishi E, Takh O, Vedvick TS, Fanger G, Stewart L, Watson GJ, Snary D, Fisher PB, Saeki T, Roth JA, Ramesh R, Chada S.

Mol Med. 2001 Apr;7(4):271-82.

42.

WT1-specific serum antibodies in patients with leukemia.

Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL, Cornellison CD, Vedvick TS, Skeiky YA, Cheever MA.

Clin Cancer Res. 2001 Mar;7(3 Suppl):761s-765s.

PMID:
11300470
43.

Cloning of a Mycobacterium tuberculosis gene encoding a purifed protein derivative protein that elicits strong tuberculosis-specific delayed-type hypersensitivity.

Coler RN, Skeiky YA, Ovendale PJ, Vedvick TS, Gervassi L, Guderian J, Jen S, Reed SG, Campos-Neto A.

J Infect Dis. 2000 Jul;182(1):224-33. Epub 2000 Jul 6.

PMID:
10882601
44.

Identification of differentially expressed genes in human prostate cancer using subtraction and microarray.

Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, Vedvick TS, Leslie KB, Badaro R, Reed SG.

Cancer Res. 2000 Mar 15;60(6):1677-82.

45.

Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis.

Webb JR, Vedvick TS, Alderson MR, Guderian JA, Jen SS, Ovendale PJ, Johnson SM, Reed SG, Skeiky YA.

Infect Immun. 1998 Sep;66(9):4208-14.

46.

Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy.

Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA.

J Immunol. 1997 Jul 1;159(1):472-80.

PMID:
9200488
47.

Molecular cloning of a major cockroach (Blattella germanica) allergen, Bla g 2. Sequence homology to the aspartic proteases.

Arruda LK, Vailes LD, Mann BJ, Shannon J, Fox JW, Vedvick TS, Hayden ML, Chapman MD.

J Biol Chem. 1995 Aug 18;270(33):19563-8.

48.

Structural analysis of the light subunit of the Entamoeba histolytica galactose-specific adherence lectin.

McCoy JJ, Mann BJ, Vedvick TS, Pak Y, Heimark DB, Petri WA Jr.

J Biol Chem. 1993 Nov 15;268(32):24223-31.

49.

Sequence analysis of genes encoding the light subunit of the Entamoeba histolytica galactose-specific adhesin.

McCoy JJ, Mann BJ, Vedvick TS, Petri WA Jr.

Mol Biochem Parasitol. 1993 Oct;61(2):325-8. No abstract available.

PMID:
8264736
50.

Recent advances in the expression of foreign genes in Pichia pastoris.

Cregg JM, Vedvick TS, Raschke WC.

Biotechnology (N Y). 1993 Aug;11(8):905-10. Review.

PMID:
7763913

Supplemental Content

Loading ...
Support Center